Merck Seeks Authorization From US Regulators for Antiviral COVID-19 Treatment

An experimental COVID-19 treatment pill called molnupiravir being developed by Merck and Ridgeback Biotherapeutics, in an undated photograph. Merck/Reuters

Merck and its partner on Oct. 11 announced that they filed an emergency use authorization application with the U.S. Food and Drug Administration (FDA) for their oral antiviral medicine for the treatment of COVID-19.

The pill is meant to combat cases of mild or moderate COVID-19.